INTRODUCTION
Studies on the treatment of adult acute lymphoblastic leukemia (ALL) have shown only modest improvements over the last two decades, with the actual cure rate remaining in the range of 15-40% (1, 2) . Novel treatment modalities have been directed toward inappropriately activated cell-signaling pathways that may be responsible for the proliferation and/or apoptosis escape of leukemic blasts (3).
The mitogen-activated protein kinase (MAPK) signaling cascade is one of the pathways that mediates the proliferation and differentiation of hematopoietic cells (4) . Among the MAPK pathways, extracellular signal-regulated kinase (ERK1/2) is activated in response to various mitogenic signals, participating in a wide range of cellular programs including cell cycle progression and differentiation (5) .
In recent years, it has been reported that constitutive ERK1/2 activation (p-ERK1/2) is frequently found in solid tumors (6, 7) , as well as in hematologic neoplastic diseases, particularly acute (9) , using a flow cytometric technique, similarly found constitutive p-ERK1/2 in 83.3% of AML cases. In addition, it has been reported (10) that p-ERK1/2 may represent an independent prognostic factor for survival in AML patients.
The availability of low molecular weight, cell membrane permeable agents targeting the MAPK pathway by inhibiting MEK-dependent ERK1/2 phosphorylation has suggested a potential role of therapeutic strategies based on MEK inhibition in diseases characterized by its constitutive activation (11, 12) .Limited information is available, at this time, on the presence and role of constitutive ERK1/2 signaling activation in ALL. Constitutive ERK1/2 activation in ALL cell lines and in a limited number of clinical ALL specimens has been reported (13, 14) . The aim of our study was to evaluate the frequency of p-ERK1/2 expression in primary blasts from adult ALL cases enrolled in the GIMEMA LAL2000 multicenter study and to correlate p-ERK1/2 expression with different clinical and biological prognostic factors.
STUDY DESIGN
The study was approved by the Institutional Review Board of the Department of Cellular Biotechnologies and Hematology, University "La Sapienza" of Rome. Bone marrow (BM) and/or peripheral blood (PB) samples for p-ERK1/2 studies were obtained at initial diagnosis from adult ALL patients enrolled in the GIMEMA LAL2000 multicenter study. This study was performed on 518 enrolled patients, of which 455 were evaluated for response to chemotherapy. 
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According to the GIMEMA LAL2000 study protocol, therapy consisted of a 7-day pre-phase with prednisone (PDN 20mg/smq) followed by standard induction chemotherapy. The protocol is described in the supplementary material. Response to the steroid pre-phase (peripheral blast cell count at day 0<1000/µL) was also evaluated in the study. Post-induction treatment and response criteria have been described elsewhere (15, 16) . p-ERK1/2 expression was preliminarily evaluated in leukemic cell lines and in unstimulated and PMA-activated normal peripheral blood and leukemic primary samples (see supplementary information). For the propose of this study, clinical samples were evaluated by a flow cytometric technique as previously described (9, 17) . Cell cycle distribution was evaluated as previously described (18) . p-ERK1/2 flow cytometric expression was analyzed using the Kolmogorov-Smirnov statistic test (D value) (16) . Protein expression was represented as either a continuous or a dichotomized variable: samples with a D-value ≥0.10 were considered positive. In order to assess the differences between groups, Chi-squared and Fisher-exact-tests were performed. The SAS software (SAS Institute, Cary, NC) was used for the analysis.
RESULTS and DISCUSSION
This study was conducted to determine whether the MAPK pathway, specifically ERK1/2, is constitutively activated in adult ALL cells and may therefore represent a potential therapeutic target (19) . In the present study, we have evaluated the largest series of clinical samples reported to date. Table 1 Table 2 reports the clinical and biological characteristics of the 131 patients according to p-ERK1/2 expression. No significant association was observed between p-ERK1/2 expression and age or immunophenotype. Interestingly, the expression of p-ERK1/2 was significantly associated with the WBC counts ( Table 2 ). Higher levels of p-ERK1/2, in fact, directly correlated with a higher WBC count expressed as logarithmic scale (r=0.17; P=0.05) (Fig 1) , while cell cycle distribution did not (see table S1 ). We also noticed that ALL samples expressing the CD34 antigen were inversely associated with p-ERK1/2 expression (P=0.0026). No significant association was observed between p-ERK1/2 expression and cytogenetic and molecular groups: in particular, BCR/ABL+ patients were not significantly associated with p-ERK1/2, both when analyzed by dichotomized variable (Table 2 ) and by continuous variable (P=n.s). Of relevance, p-ERK1/2 expression (dichotomized variable) was found in 44.1% (15/34) of steroid non-responder patients vs 27.7% (18/65) of cases with day 0 blasts <1000 (responders) (P=0.099). We then evaluated in the study population (see Table S2 ) the prognostic role of known clinical/biological parameters (age, WBC counts, blast reduction following the steroid pre-phase, phenotype and BCR/ABL translocation) and p-ERK1/2 expression. Blast reduction significantly affected CR achievement (P=0.015) and a trend-significant association was found between lower p-ERK1/2 (continuous variable) and higher probability of achieving CR (P=0.069) (Fig 1) . The BCR/ABL translocation was not a prognostic factor for CR achievement in this series of patients (P=n.s.). Multivariate analysis was performed to evaluate the impact of p-ERK1/2 expression on achievement of CR in a model which included WBC values and blast reduction following the steroid pre-phase. Among 99 patients evaluable for these parameters, p-ERK1/2 was an independent predictor of CR (P=0.027; Odd Ratio 0.040; 95%Cl 0.002-0.693), together with blast reduction (P=0.0094), while WBC counts were not. Conversely, p-ERK1/2 expression failed to predict CCR, OS and EFS. Multivariate analysis confirmed these results showing that in our population only blast reduction and age influenced EFS (P=0.
P=0
.038, respectively), while WBC (P=0.89), immunophenotype (P=0.58), BCR/ABL (P=0.54) and p-ERK1/2 (P=0.19) did not.
In conclusion, our data obtained in this large series of patients uniformly enrolled in a multicenter clinical trial, indicate that p-ERK1/2 is consistently expressed in a proportion of adult ALL, is associated with poor prognostic factors (higher WBC counts and failure to respond to steroid prephase) and independently affects achievement of CR. Small-molecule inhibitors effectively targeting the MAPK pathway and/or other potentially involved signaling pathways, such as the PI3K/Akt/mTOR cascade (20, 21) , must be evaluated, to establish whether this targeted therapeutic modality may add benefit (anti-proliferative/pro-apoptotic) to the current treatment of adult ALL. Correlation between p-ERK1/2 expression and response to treatment. A trend (P=0.069) was found between lower phosphoprotein level (continuous variable) and higher probability of achieving CR. 
